Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new pill tame fungal infections when standard drugs fail?

NCT ID NCT07804368

Disease control Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This Phase 2 trial tests an oral antifungal drug called oteseconazole in adults with dimorphic fungal infections, including coccidioidomycosis, blastomycosis, and histoplasmosis. Participants must already be on antifungal therapy but need a different option because standard first-line treatment is not working, causes side effects, or is unavailable. Researchers will track symptoms, daily function, safety, and quality of life during treatment and for up to 6 months after. The goal is to see if oteseconazole can safely control these infections as a salvage or consolidation therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oteseconazole (also known as VIVJOA), an oral antifungal drug
What this could lead to
If it works, oteseconazole could offer a new treatment option for people with serious fungal infections who cannot tolerate or do not respond to standard antifungal drugs.
What could go wrong
This is an early-stage trial with only 30 participants, so results may not apply to everyone. The drug may cause side effects or may not control the infection better than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of coccidioidomycosis, blastomycosis, or histoplasmosis and on active therapy * Age 18 years or older * Anticipated need for at least 6 additional months of antifungal therapy at enrollment * Intolerance, failure, or unavailability of current first-line consolidation therapy Exclusion Criteria: * Currently hospitalized * Central nervous system involvement of coccidioidomycosis, blastomycosis, or histoplasmosis * Previous administration of or allergy to study drug * Any condition for which participation would not be in the best interest of the participant or that could limit protocol-specified assessments * Females of childbearing potential * Breast Cancer Resistance Protein substrate medication interaction that cannot be managed by switching medication, discontinuation, 50% dose reduction, or use of the lowest dose * Children * Pregnant women/persons * Fetuses * Neonates * Prisoners * Adults lacking capacity to consent or adults with diminished or fluctuating capacity to consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blastomycosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blastomycosis coccidioidomycosis histoplasmosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blastomycosis Coccidioidomycosis Dimorphic fungal infection Endemic mycoses Histoplasmosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Arizona State University - Tempe Campus

    Tempe, Arizona, 85287, United States

  • Mayo Clinic

    Phoenix, Arizona, 85054, United States

  • UCSF Fresno

    Fresno, California, 93701-2302, United States

  • University of California, Davis

    Davis, California, 95616, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.